FrancophonIA/ELRC3.0 huggingface dataset:
English: NovoSeven is a powder and solvent for injection that contains the active substance eptacog alfa (activated human recombinant coagulation factor VII).
Estonian: NovoSeven on pulber ja lahus süstimiseks, mis sisaldab toimeainena eptakog-alfat (aktiveeritud rekombinantne VII inimhüübimistegur).
English: NovoSeven was expected to limit the bleeding, and so reduce the consequences of the intracerebral haemorrhage.
Estonian: NovoSeven pidi piirama verevalumit ja sel viisil vähendama intratserebraalse hemorraagia tagajärgi.
English: How is NovoSeven expected to work in this indication?
Estonian: Kuidas kavatseti NovoSevenit selle näidustuse korral kasutada?
English: NovoSeven is currently used for the treatment and prevention of bleeding connected with surgery in patients with haemophilia who have developed ‘inhibitors' (antibodies) to factor VIII or IX.
Estonian: Praegu kasutatakse NovoSevenit operatsiooniaegsete verejooksude ravimiseks ja vältimiseks neil hemofiiliat põdevatel patsientidel, kellel on tekkinud VIII või IX hüübimisteguri inhibiitorid (antikehad).
English: The effectiveness of NovoSeven was assessed by looking at its effect on the volume of the haemorrhage inside the brain, measured using a scan (percentage change in the volume after 24 hours of treatment with NovoSeven or placebo).
Estonian: NovoSeveni tõhususe hindamisel analüüsiti ravimi toimet ajusisese hemorraagia suurusele (mahu protsentuaalne muutumine 24 tunni järel pärast NovoSeveni või platseebo annustamist), mida mõõdeti kompuutertomograafiaga.
English: It is also used in patients with acquired haemophilia, in patients with congenital factor VII deficiency, and in patients with Glanzmann's thrombasthenia (a rare bleeding disorder) who cannot be treated by a transfusion of platelets.
Estonian: Ravimit kasutatakse ka omandatud hemofiilia, VII hüübimisteguri kaasasündinud puuduse või Glantzmanni tõvega (harva esinev veritsushäire) patsientidel, kellele ei saa trombotsüüte (vereliistakuid) üle kanda.
English: In intracerebral haemorrhage, NovoSeven is expected to slow down the bleeding and the spread of the haemorrhage, thus improving the outcome for the patient.
Estonian: NovoSeven eeldatavasti aeglustab intratserebraalse hemorraagia puhul veritsust ja hemorraagia edasiarenemist ning seeläbi parandab patsiendi seisundit.
English: NovoSeven was to be used to treat adult patients with intracerebral haemorrhage (bleeding inside the brain).
Estonian: NovoSevenit kavatseti kasutada täiskasvanud patsientide raviks, kellel on intratserebraalne hemorraagia (ajusisene verevalum).
English: NovoSeven contains eptacog alfa (activated), which is a blood coagulation factor protein.
Estonian: NovoSeven sisaldab eptakog-alfat (aktiveeritud), mis on vere hüübimisteguriks nimetatav valk.
English: The CHMP normally takes up to 90 days (with the possibility to extend it to another 90 days) to adopt an opinion after it has received an application for a change to a marketing authorisation.
Estonian: Pärast müügiloa muutmise taotluse saamist kulub inimtervishoius kasutatavate ravimite komitee arvamuse vastuvõtmiseni tavaliselt kuni 90 päeva (ajavahemikku võidakse pikendada veel 90 päeva võrra).
English: London, 27 April 2006 Doc.Ref.
Estonian: London, 27. aprill 2006 CHMP/154955/2006
English: What was NovoSeven expected to be used for this indication?
Estonian: Milline pidi olema NovoSeveni toime selle näidustuse suhtes?
English: The main concern of the CHMP was that the data were too limited to evaluate the benefit and the potential risks of NovoSeven in intracerebral haemorrhage.
Estonian: Inimtervishoius kasutatavate ravimite komitee ettevaatlikkust põhjustas peamiselt andmete vähesus, mille põhjal hinnata NovoSeveni kasulikkust intratserebraalse hemorraagia raviks või sellise raviga kaasnevaid võimalikke ohtusid.
English: In the body, eptacog alfa acts like one of the substances involved in blood coagulation (clotting), Factor VII.
Estonian: Eptakog-alfa toimib kehas nagu VII hüübimistegur, teatud aine, mis osaleb vere hüübimisel.
English: The full EPAR for Entecavir Mylan can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Entecavir Mylan kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It can also be considered for children aged from 2 to 18 years but only in those with compensated liver disease.
Estonian: Ravimi kasutamist võib kaaluda ka 2-18-aastastel lastel, kuid üksnes kompenseeritud maksahaiguse korral.
English: The 1 mg daily dose is also used in adults with decompensated liver disease and stopping treatment is not recommended in these patients.
Estonian: 1 mg ööpäevast annust kasutatakse ka dekompenseeritud maksahaigusega täiskasvanud patsientidel ja nendel patsientidel ei soovitata ravi katkestada.
English: What measures are being taken to ensure the safe and effective use of Entecavir Mylan?
Estonian: Mis meetmed võetakse, et tagada ravimi Entecavir Mylan ohutu ja efektiivne kasutamine?
English: The European Medicines Agency concluded that, in accordance with EU requirements, Entecavir Mylan has been shown to have comparable quality and to be bioequivalent to Baraclude.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Entecavir Mylan võrreldav kvaliteet ja bioekvivalentsus ravimiga Baraclude.
English: Entecavir Mylan is taken once a day.
Estonian: Ravimit Entecavir Mylan võetakse üks kord ööpäevas.
English: Entecavir Mylan can only be obtained with a prescription and is available as tablets (0.5 mg and 1 mg).
Estonian: Entecavir Mylan on retseptiravim ja seda turustatakse tablettidena (0,5 mg ja 1 mg).
English: For adults with compensated liver disease, the dose depends on whether or not the patient has been previously treated with a medicine in the same group as Entecavir Mylan (a nucleoside analogue, such as lamivudine).
Estonian: Kompenseeritud maksahaigusega täiskasvanutel sõltub annus sellest, kas patsienti on või ei ole varem ravitud ravimiga, mis kuulub ravimiga Entecavir Mylan samasse rühma (nukleosiidianaloogiga, näiteks lamivudiiniga).
English: When treatment is considered appropriate in children, the dose depends on their body weight.
Estonian: Kui laste ravi peetakse vajalikuks, sõltub annus nende kehamassist.
English: As for every medicine, the company provided studies on the quality of Entecavir Mylan.
Estonian: Nagu iga ravimi korral, esitas ettevõte uuringud ravimi Entecavir Mylan kvaliteedi kohta.
English: Patients who have not been treated before with a nucleoside analogue receive a 0.5 mg dose, while those who have received lamivudine before but whose infection is no longer responding to it are given a 1 mg dose.
Estonian: Patsientidel, keda ei ole varem nukleosiidianaloogiga ravitud, kasutatakse 0,5 mg annust, kuid nendel varem lamivudiiniga ravitud patsientidel, kelle nakkus enam ravile ei allu, kasutatakse 1 mg annust.
English: Entecavir Mylan entecavir
Estonian: Entecavir Mylan entekaviir
English: This means that Entecavir Mylan contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Baraclude.
Estonian: See tähendab, et Entecavir Mylan sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Baraclude, millel juba on Euroopa Liidus müügiluba.
English: Children weighing 32.6 kg and above can be given the 0.5 mg tablets, while an oral solution of entecavir should be used for children weighing less than 32.6 kg. For further information, see the package leaflet.
Estonian: Vähemalt 32,6 kg kaaluvatele lastele tohib anda 0,5 mg tablette, kuid alla 32,6 kg kaaluvatel lastel tuleb kasutada entekaviiri suukaudset lahust.
English: Entecavir Mylan is a medicine used to treat chronic (long-term) hepatitis B (an infectious disease of the liver, caused by the hepatitis B virus).
Estonian: Entecavir Mylan on ravim, mida kasutatakse kroonilise (pikaajalise) B-hepatiidi (B-hepatiidi viiruse põhjustatud nakkuslik maksahaigus) raviks.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Baraclude, and do not need to be repeated for Entecavir Mylan.
Estonian: Võrdlusravimiga Baraclude on juba tehtud toimeaine heakskiidetud kasutusviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Entecavir Mylan korrata.
English: Because Entecavir Mylan is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Entecavir Mylan on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: The Agency recommended that Entecavir Mylan be approved for use in the EU.
Estonian: Ravimiamet soovitas ravimi Entecavir Mylan kasutamise Euroopa Liidus heaks kiita.
English: This is a summary of the European public assessment report (EPAR) for Entecavir Mylan.
Estonian: See on ravimi Entecavir Mylan Euroopa avaliku hindamisaruande kokkuvõte.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Entecavir Mylan have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Entecavir Mylan ohutu ja efektiivse kasutamise soovitused ning ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Treatment with Entecavir Mylan should be started by a doctor with experience in the management of chronic hepatitis B.
Estonian: Ravi Entecavir Mylaniga peab alustama kroonilise B-hepatiidi ravis kogenud arst.
English: Entecavir Mylan contains the active substance entecavir and is a ‘generic medicine'.
Estonian: Entecavir Mylan sisaldab toimeainena entekaviiri ja see on geneeriline ravim.
English: What is Entecavir Mylan and what is it used for?
Estonian: Mis on Entecavir Mylan ja milleks seda kasutatakse?
English: For practical information about using Entecavir Mylan, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Entecavir Mylan kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Why is Entecavir Mylan approved?
Estonian: Miks Entecavir Mylan heaks kiideti?
English: Therefore, the Agency's view was that, as for Baraclude, the benefit outweighs the identified risk.
Estonian: Seetõttu on amet arvamusel, et nagu ka Baraclude korral, ületab ravimi Entecavir Mylan kasulikkus sellega kaasnevad riskid.
English: For more information about treatment with Entecavir Mylan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Entecavir Mylan toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Entecavir Mylan
Estonian: Muu teave ravimi Entecavir Mylan kohta
English: The active substance in Entecavir Mylan, entecavir, is an antiviral belonging to the class of the nucleoside analogues.
Estonian: Ravimi Entecavir Mylan toimeaine entekaviir on nukleosiidianaloogide klassi kuuluv viirusevastane ravim.
English: It is not intended to provide practical advice on how to use Entecavir Mylan.
Estonian: Hindamisaruandes ei anta ravimi Entecavir Mylan kasutamise praktilisi nõuandeid.
English: How has Entecavir Mylan been studied?
Estonian: Kuidas ravimit Entecavir Mylan uuriti?
English: How is Entecavir Mylan used?
Estonian: Kuidas Entecavir Mylan toimib?
English: What are the benefits and risks of Entecavir Mylan?
Estonian: Milles seisneb ravimi Entecavir Mylan kasulikkus ja mis riskid ravimiga kaasnevad?
English: Do not take more than 1 tablet per day.
Estonian: Ärge võtke rohkem kui üks tablett ööpäevas.
English: Duzallo should be taken in the morning with food and water.
Estonian: Duzallot tuleb võtta hommikuti koos toidu ja veega.
English: A specific antidote is unknown.
Estonian: Spetsiifiline antidoot on teadmata.
English: Wait and take your next dose of Duzallo the next morning.
Estonian: Oodake ja võtke järgmine Duzallo annus järgmisel hommikul.
English: Experience in very elderly patients (≥75 years) is limited.
Estonian: Kogemused väga eakate patsientidega (≥ 75-aastased) on piiratud.
English: Elderly (≥65 years)
Estonian: Eakad (≥ 65-aastased)
English: Other medicines and Duzallo
Estonian: Muud ravimid ja Duzallo
English: Concomitant use which needs to be taken into consideration:
Estonian: Samaaegsel kasutamisel tuleb arvestada järgnevaga:
English: None of these were serious or required hospitalisation.
Estonian: Ükski kõrvaltoimetest ei olnud raske ega vajanud haiglaravi.
English: The recommended dose is 1 tablet once a day in the morning.
Estonian: Soovitatav annus on üks tablett üks kord ööpäevas hommikuti.
English: Do not stop taking Duzallo without talking to your doctor first even if you feel better.
Estonian: Ärge lõpetage Duzallo võtmist ilma kõigepealt arstiga nõu pidamata isegi siis, kui tunnete ennast paremini.
English: The large discrepancies in these values may be accounted for by variations in study design and/or creatinine clearance in the patients.
Estonian: Nende väärtuste suured lahknevused võivad olla tingitud erinevustest uuringu ülesehituses ja/või patsientide kreatiniini kliirensis.
English: Alternative methods of contraception should be considered.
Estonian: Kaaluma peab alternatiivsete rasestumisvastaste vahendite kasutamist.
English: ATC code: M04AA51
Estonian: ATC-kood: M04AA51
English: Difference in proportion (95% C.I.)
Estonian: Osakaalude erinevus (95% CI)
English: HLA-B*5801 allele
Estonian: HLA-B*5801 alleel
English: - you have or have had heart failure or other heart problems - your gout gets worse
Estonian: - kui teil on või on esinenud südamepuudulikkust või muid südameprobleeme - kui teie podagra ägeneb
English: The safety and efficacy of Duzallo in children and adolescents under 18 years of age have not yet been established.
Estonian: Duzallo ohutus ja efektiivsus lastel ja noorukitel vanuses alla 18 aasta ei ole veel tõestatud.
English: If such reactions do occur, it may be at any time during treatment, Duzallo should be withdrawn immediately and permanently.
Estonian: Kui sellised reaktsioonid ilmnevad, ja seda võib juhtuda mis tahes hetkel ravi ajal, tuleb Duzallo-ravi kohe ja jäädavalt lõpetada.
English: Coadministration of these 2 active substances is generally not recommended.
Estonian: Nende kahe toimeaine koosmanustamine ei ole üldiselt soovitatav.
English: Opaque (PVC/PVdC/Aluminium) blister.
Estonian: Läbipaistmatu (PVC/PVdC/alumiinium) blisterpakend.
English: Most of the radioactivity recovered in urine (>60% of dose) occurred in the first 24 hours.
Estonian: Suurem osa uriiniga eritunud radioaktiivsusest (> 60% annusest) eritus esimese 24 tunni jooksul.
English: These serious skin reactions can be more common in:
Estonian: Neid raskeid nahareaktsioone võib esineda sagedamini:
English: This is because Duzallo can affect the way some other medicines work.
Estonian: Seda sellepärast, et Duzallo võib mõjutada mõnede ravimite toimet.
English: The clinical relevance is not clear.
Estonian: Leiu kliiniline tähtsus on ebaselge.
English: These serum creatinine elevations generally resolved, most without treatment interruption.
Estonian: Seerumi kreatiniinisisalduse suurenemine üldiselt lahenes, enamasti ilma ravi katkestamiseta.
English: If concomitant use is unavoidable, a dose reduction of didanosine may be required, and patients should be closely monitored.
Estonian: Kui kooskasutamine on vältimatu, võib vajalikuks osutuda didanosiini annuse vähendamine ning patsiente tuleb hoolikalt jälgida.
English: Duzallo is a tablet to be taken by mouth.
Estonian: Duzallo on tablett, mida võetakse suu kaudu.
English: • people of Han Chinese, Thai or Korean origin
Estonian: • han-hiinlastel, Tai või Korea päritolu inimestel;
English: This is also the maximum daily dose of Duzallo (see section 4.4).
Estonian: See on ka Duzallo maksimaalne ööpäevane annus (vt lõik 4.4).
English: Studies in animals with lesinurad do not indicate direct or indirect harmful effects.
Estonian: Lesinuraadiga tehtud loomkatsed ei näita otsest või kaudset kahjulikku toimet.
English: Oxypurinol AUC and Cmax was not affected by food.
Estonian: Oksüpurinooli AUC ja Cmax väärtusi toit ei mõjutanud.
English: Adverse reactions are classified according to frequency and System Organ Class.
Estonian: Kõrvaltoimed on liigitatud lähtuvalt esinemissagedusest ja organsüsteemi klassist.
English: Estimates range from 13 to 30 hours in man.
Estonian: Inimesel jääb see hinnanguliselt vahemikku 13...30 tundi.
English: Children and adolescents Duzallo is not recommended for use in children and adolescents below 18 years of age.
Estonian: Lapsed ja noorukid Duzallot ei soovitata kasutada lastel ja alla 18-aastastel noorukitel.
English: The cause of the reported association has not been established.
Estonian: Teatatud seose põhjus ei ole kindlaks tehtud.
English: The use of genotyping has not been established in other patient populations.
Estonian: Teistes patsiendirühmades ei ole genotüpseerimist kehtestatud.
English: In vitro and in vivo studies conducted to date showed no evidence of mutagenic or carcinogenic potential.
Estonian: Tänaseni tehtud in vitro ja in vivo uuringutes ei ole leitud tõendeid võimaliku mutageense või kantserogeense toime kohta.
English: There is no specific treatment in the event of an overdose, and symptoms of overdose are not established.
Estonian: Üleannustamise korral spetsiifiline ravi puudub ja üleannustamise sümptomeid ei ole kindlaks tehtud.
English: Swallow the tablet whole with water and after breakfast in the morning.
Estonian: Neelake tablett hommikul pärast hommikusööki tervelt alla koos veega.
English: However, no data are available.
Estonian: Vastavad andmed aga puuduvad.
English: In another patient the intake of 22.5 g allopurinol caused no adverse reactions.
Estonian: Teisel patsiendil ei põhjustanud 22,5 g allopurinooli mingeid kõrvaltoimeid.
English: Clinically relevant interactions with other medicinal products
Estonian: Kliiniliselt olulised koostoimed teiste ravimpreparaatidega
English: These serious skin rashes often come after flu-like symptoms such as fever, headache, body ache.
Estonian: Need rasked nahalööbed tekivad tihti pärast gripilaadseid sümptomeid nagu palavik, peavalu, valulik keha.
English: Reported values for the elimination half-life range from 13.6 hours to 29 hours.
Estonian: Teadete põhjal jääb eritumise poolväärtusaeg vahemikku 13,6...29 tundi.
English: Renal clearance is 25.6 mL/min (coefficient of variation CV=56%).
Estonian: Neerukliirens on 25,6 ml/min (variatsioonikoefitsient (CV) = 56%).
English: The frequency of the HLA-B*5801 allele varies widely between ethnic populations: up to 20% in Han Chinese population, 8-15% in the Thai, about 12% in the Korean population and 1-2% in individuals of Japanese or European origin.
Estonian: HLA-B*5801 alleeli esineb erinevates etnilistes rühmades erineval määral: han-hiinlastel kuni 20% rahvastikust, Tais 8...15%, Koreas ligikaudu 12% rahvastikust ning Jaapani või Euroopa päritolu inimestel 1…2% rahvastikust.
English: **** The occurrence of increased thyroid stimulating hormone (TSH) in the relevant studies did not report any impact on free T4 levels or had TSH levels indicative of subclinical hypothyroidism.
Estonian: **** Kilpnääret stimuleeriva hormooni (TSH) sisalduse suurenemise juhtudel ei teatatud asjakohastes uuringutes mingit mõju vaba T4 sisaldusele, samuti ei viidanud TSH sisaldus subkliinilisele hüpotüreoidismile.
English: Drink plenty of water during the day to reduce the risk of kidney stones.
Estonian: Jooge päeva jooksul rohkesti vett, see aitab vähendada neerukivide tekkeriski.
English: Vidarabine (Adenine Arabinoside)
Estonian: Vidarabiin (adeniinarabinosiid)
English: Tumour lysis syndrome or Lesch-Nyhan syndrome.
Estonian: Tuumorilüüsi sündroomi või Leschi-Nyhani sündroom.
English: Duzallo may cause serious kidney problems (see section 4).
Estonian: Duzallo võib põhjustada raskeid neeruprobleeme (vt lõik 4).
English: Skin reactions are the most common reactions and may occur at any time during treatment.
Estonian: Nahareaktsioonid on kõige sagedasemad ja võivad tekkida ravi igal ajahetkel.
English: Tell your doctor or pharmacist if you are taking any of the following:
Estonian: Teavitage oma arsti või apteekrit, kui võtate ükskõik millist järgnevat ravimit:
English: All patients receiving coumarin anticoagulants must be carefully monitored.
Estonian: Kõiki kumariini tüüpi antikoagulante saavaid patsiente tuleb hoolikalt jälgida.
English: What Duzallo contains
Estonian: Mida Duzallo sisaldab
English: Following multiple once daily dosing of lesinurad, there was no evidence of time dependent changes in pharmacokinetic properties and dose proportionality was preserved.
Estonian: Pärast lesinuraadi korduvat manustamist üks kord ööpäevas ei täheldatud ajast sõltuvaid muutusi farmakokineetilistes omadustes ning annuse proportsionaalsus jäi samaks.
English: CYP2B6 has not been studied in vivo.
Estonian: CYP2B6-ga ei ole in vivo uuringuid tehtud.
English: Lesinurad 200 mg + allopurinol N=405
Estonian: 200 mg lesinuraadi + allopurinool N = 405
English: They may be pruritic, maculopapular, sometimes scaly, sometimes purpuric and rarely exfoliative, such as SJS/TEN.
Estonian: Need võivad olla kihelevad, makulopapulaarsed, mõnikord ketendavad, mõnikord purpuralaadsed ja harva eksfoliatiivsed, nt SJS/TEN.
English: If an overdose is suspected, patients should be managed by symptomatic and supportive care including adequate hydration.
Estonian: Üleannustamise kahtlusel tuleb patsiente ravida sümptomaatiliste ja toetavate meetmetega, sh tagada adekvaatne hüdratsioon.
English: Extra vigilance for signs of hypersensitivity syndrome or SJS/TEN is required and the patient should be informed of the need to stop treatment immediately at the first appearance of symptoms.
Estonian: Ülitundlikkussündroomi või SJS/TEN-i nähtude tekke suhtes tuleb olla eriti valvas ja patsienti tuleb teavitada vajadusest peatada ravi kohe esimeste sümptomite avaldumisel.
English: Hypersensitivity If you have a hypersensitivity (allergic) reaction, stop taking Duzallo and see a doctor immediately.
Estonian: Ülitundlikkus Kui teil tekib ülitundlikkusreaktsioon (allergiline reaktsioon), lõpetage Duzallo võtmine ja pöörduge kohe arsti poole.
English: Blood count monitoring should therefore be performed at regular intervals.
Estonian: Seetõttu tuleb regulaarselt jälgida kliinilise vere analüüsi.
English: • people who have problems with their kidneys and take this medicine and a diuretic (a medicine that increases urine) at the same time
Estonian: • inimestel, kellel on probleeme neerudega ja kes võtavad samaaegselt selle ravimiga diureetikume (ravimeid, mis suurendavad väljutatava uriini hulka).
English: Frequency categories are defined according to the following conventions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10000 to <1/1000) and very rare
Estonian: Esinemissageduse kategooriad on määratletud järgmiselt: väga sage (≥ 1/10); sage (≥ 1/100 kuni < 1/10); aeg-ajalt (≥ 1/1000 kuni < 1/100); harv (≥ 1/10 000 kuni < 1/1000) ja väga harv (< 1/10 000).
English: Duzallo tablets contain lactose (a type of sugar).
Estonian: Duzallo tabletid sisaldavad laktoosi (teatud tüüpi suhkur).
English: Allopurinol has a plasma half-life of about 0.5 to 1.5 hours.
Estonian: Allopurinooli poolväärtusaeg plasmas on ligikaudu 0,5...1,5 tundi.
English: Patients with serum creatinine elevations to greater than 1.5 times the pre-treatment value should be closely monitored.
Estonian: Patsiente, kelle seerumi kreatiniinisisaldus on suurem kui 1,5-kordne ravieelne väärtus, tuleb hoolikalt jälgida.